Evaluation of intermediate and long term follow up results of the patients who underwent coronary drug eluting stent implantation

Purpose: The aim of this study is to investigate the mid and long term MACCE (major advers cardiac and cerebral events) ratio of the patients who underwent percutaneous coronary intervention and concerned coronary artery de novo stented with new generation drug eluting stents. Metodology: We scanned approximately 2150 patients who underwent percutaneous coronary intervention between December 2009 and 2013. Four hundered patients in 2150 patients were eligible for study inclusion criteria and were enrolled. The retrospective study was performed on hospital records and then appreciated for death, cerebrovascular event, myocardial enfarctus and target vessel revascularization. The MACCE was evaluated by hospital records and telephone contact. Results: Patients were followed for a period of 6-60 months. The average follow up period was 27 months [Ort ± St.error=27.8 ± 14.7]. Four hundred patients that included to the study was consisting 166 of everolimus (EES), 54 of zotarolimus (ZES), 151 of biolimus (BES) and 29 of combination of these groups. We evaluated total and according to the type of the stents MACCE ratio. In EES group; re-Mİ 3 (%1.8), TVR 5 (%3), mortality 1 (%1.9), in BES group; re-Mİ 1(%1.9), TVR 1(%1.9), mortality 1 (%1.9) and in ZES group; re-Mİ 4 (%2.6), TVR 7(%4.6), mortality 6 (%4) were calculated. No serebrovascular event was enrolled during and postintervention period. Conclusion: The MACCE ratio %7.8 in the group of EES,%5.5 in the group of BES and %11.5 in the group of ZES were measured. When we evaluated the hole data (400 patients) after new generation drug eluting stent implantation, the MACCE ratio was measured %8.25. Key Words: Percutaneus coronary intervention, drug eluting stents.